Myriad Genetics Inc (MYGN) Posted -14.08% Profit Margin Last Year—Can It Hold Up?

UBS has recently initiated Myriad Genetics Inc (MYGN) stock to Neutral rating, as announced on December 10, 2024, according to Finviz. Earlier, on December 9, 2024, Leerink Partners had reduced the stock from a Outperform to Market Perform, setting a price target of $21 for MYGN stock. Morgan Stanley also initiated research coverage with a price target of $32. Additionally, Wells Fargo initiated Overweight rating on August 28, 2024, with a target price of $35. Scotiabank analysts, in their report published on June 27, 2024, also initiated Sector Outperform rating and set a price target of $29 for Myriad Genetics Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.

Myriad Genetics Inc (MYGN) Stock Trading Recap

On Friday, Myriad Genetics Inc (MYGN) stock saw a decline, ending the day at $12.39 which represents a decrease of $-0.13 or -1.04% from the prior close of $12.52. The stock opened at $12.56 and touched a low of $12.21 during the day, reaching a high of $12.84. The volume of shares traded was 0.93 million falling short of the average volume of 0.97 million.


Sponsored

MYGN Stock Performance and Moving Averages

In recent trading, Myriad Genetics Inc (MYGN) stock price has shown some volatility, fluctuating -16.45% over the last five trades and -12.25% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -53.44%, and it has plunged by -48.20% in the previous three months. Currently, MYGN is trading at -9.00%, -16.95%, and -43.75% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.

As of the latest trading close, MYGN, a Healthcare sector stock, is trading -57.71% below its 52-week high but remains 1.81% above its 52-week low. The Average True Range (ATR) (14 days) of 0.82 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.

Myriad Genetics Inc’s Profitability and Valuation Ratios

Myriad Genetics Inc’s profitability metrics reveal financial health. The company currently boasts an operating margin of -12.53% and a profit margin of -14.08%, with a gross margin of -53.44%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.

In terms of valuation, Myriad Genetics Inc’s market capitalization stands at $1.13 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. The forward P/E ratio, which uses projected earnings for the next financial year, is 84.85. Additionally, the Price-to-Sales Ratio is 1.37, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 1.54, comparing the market value to the company’s book value.

Understanding Insider Trading

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 3.75% of Myriad Genetics Inc (MYGN)’s shares, while financial institutions hold 100.54%.

Notable insider trades include DIAZ PAUL J, President and CEO at Myriad Genetics Inc (MYGN), who sold 15000 shares on Oct 11 ’24, at $22.93 each, totaling $0.34 million. On Sep 11 ’24, DIAZ PAUL J, President and CEO, sold 15000 shares for $26.72 each, amounting to $0.40 million. Additionally, on Sep 09 ’24, Dreismann Heinrich sold 10000 shares at $27.05 each, generating $0.27 million.

Related Posts

Unlock Your Investment Potential: Get Your 100% Free eBook

Best Space Stocks To Buy

A detailed analysis of Three Best Space Stocks to Buy, each selected based on Innovations, Growth Metrics & Achievements

No thanks

Best Space Stocks to Buy!

Unlock Your Investment Potential: Get Your 100% Free eBook

A Detail Analysis of Three Best Space Stocks to Buy, Eash Selected Based on Innovations, Growth Metrics & Achievements